Tumour budding in pancreatic cancer revisited: validation of the <scp>ITBCC</scp> scoring system

Karamitopoulou, Evanthia; Wartenberg, Martin; Zlobec, Inti; Cibin, Silvia; Worni, Mathias; Gloor, Beat; Lugli, Alessandro

doi:10.1111/his.13508

Cited by 35 publications

(36 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumour budding is a hallmark of cancer invasion and has been recently validated as a promising prognostic marker in colon cancer, oesophageal cancer, pancreatic cancer, lung cancer and oral cancer . Interestingly, the meta‐analyses conducted on the published studies confirm the prognostic value of tumour budding in oesophageal, colorectal and oral cancers .…”

Section: Discussionmentioning

confidence: 94%

“…In oral squamous cell carcinoma, evaluation of tumour budding using cytokeratin produced higher reproducibility than H&E staining, and interobserver variation was higher among less experienced examiners . Indeed, while pan‐cytokeratin staining can detect more tumour budding, H&E staining has been used successfully in several studies with good reliability and reproducibility . Thus, at present routine assessment of tumour budding with H&E staining can be used, while pan‐cytokeratin staining may be considered in selected cases.…”

Section: Discussionmentioning

confidence: 99%

“…38 Indeed, while pan-cytokeratin staining can detect more tumour budding, 39 H&E staining has been used successfully in several studies with good reliability and reproducibility. 11,25,30 Thus, at present routine assessment of tumour budding with H&E staining can be used, while pan-cytokeratin staining may be considered in selected cases. For example, immunostaining could be used if there is a high density of inflammatory infiltrate preventing accurate evaluation of tumour budding.…”

Section: Discussionmentioning

confidence: 99%

“…The international tumour budding consensus conference 2016 (ITBCC 2016) introduced guidelines to standardise the scoring system of this prognostic marker in colorectal cancer . Interestingly, a recent study on pancreatic cancer used the aforementioned ITBCC evaluation method of ITBCC 2016, and found that this method represents a simple and standardised scoring system that facilitates inclusion of tumour budding in pathology reports. The recommendations included 11 statements, starting with a definition of tumour budding in colorectal cancer as: ‘a single tumour cell or a cell cluster consisting of four tumour cells or less’ and ending with a statement indicating that: ‘Tumour budding and tumour grade are not the same’.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Does evaluation of tumour budding in diagnostic biopsies have a clinical relevance? A systematic review

et al. 2019

View full text Add to dashboard Cite

Tumour budding has emerged as a promising prognostic marker in many cancers. We systematically reviewed all studies that evaluated tumour budding in diagnostic biopsies. We conducted a systematic review of PubMed, MEDLINE, Scopus, Web of Science and Cochrane library for all articles that have assessed tumour budding in diagnostic (i.e. pretreatment or pre‐operative) biopsies of any tumour type. Two independent researchers screened the retrieved studies, removed duplicates, excluded irrelevant studies and extracted data from the eligible studies. A total of 13 reports comprising 11 cohorts were found to have studied tumour budding in diagnostic biopsies. All these reports showed that evaluation of tumour budding in diagnostic biopsies was easily applicable. A strong association was observed between tumour budding score in diagnostic biopsies and corresponding surgical samples. Evaluation of tumour budding in diagnostic biopsies had a significant prognostic value for lymph node metastasis and patient survival. In all studies, tumour budding was a valuable marker of tumour aggressiveness and can be evaluated in technically satisfactory diagnostic biopsies. Thus, the assessment of tumour budding seems to identify the behaviour of cancer, and therefore to facilitate treatment planning.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Does evaluation of tumour budding in diagnostic biopsies have a clinical relevance? A systematic review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Recent studies on colorectal and other gastrointestinal cancers have shown that careful analysis of tumour budding [Tb] and poorly differentiated clusters [PDCs] at the tumour invasion front may substantially improve their prognostic evaluation. [6][7][8][9][10][11][12][13] The aim of this study was to evaluate these histological parameters [Tb and PDCs] on a relatively large series of CrD-SBCs collected through the Small Bowel Cancer Italian Consortium, and hopefully to improve the prognostic characterisation of this poorly known and relatively rare subset of cancers.…”

Section: Introductionmentioning

confidence: 99%

Separation of Low- Versus High-grade Crohn’s Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis

Arpa

Grillo

Giuffrida

et al. 2019

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Background and Aims Crohn’s disease-associated small bowel carcinoma is a rare event, usually reported to have a severe prognosis. However, in previous investigations we have found a minority of cases displaying a relatively favourable behaviour, thus outlining the need to improve the histopathological prediction of Crohn’s disease-associated small bowel carcinoma prognosis. Methods As in recent studies on colorectal cancer, a substantial improvement in prognostic evaluations has been provided by the histological analysis of the tumour invasive front; we therefore systematically analysed the tumour budding and poorly differentiated clusters in the invasive front of 47 Crohn’s disease-associated small bowel carcinomas collected through the Small Bowel Cancer Italian Consortium. Results Both tumour budding and poorly differentiated cluster analyses proved highly effective in prognostic evaluation of Crohn’s disease-associated small bowel carcinomas. In addition, they retained prognostic value when combined with two other parameters, i.e. glandular histology and stage I/II, both known to predict a relatively favourable small bowel carcinoma behaviour. In particular, association of tumour budding and poorly differentiated clusters in a combined invasive front score allowed identification of a minor subset of cancers [12/47, 25%] characterised by combined invasive front low grade coupled with a glandular histology and a low stage [I or II] and showing no cancer-related death during a median follow-up of 73.5 months. Conclusions The improved distinction of lower- from higher-grade Crohn’s disease-associated small bowel carcinomas provided by invasive front analysis should be of potential help in choosing appropriate therapy for these rare and frequently ominous neoplasms.

show abstract

Post‐neoadjuvant assessment of tumour budding according to ITBCC subgroups delivers stage‐ and regression‐grade independent prognostic information in intestinal‐type gastric adenocarcinoma

Jesinghaus

Herz

Kohlruss

et al. 2022

The Journal of Pathology CR

View full text Add to dashboard Cite

Tumour budding (TB) has been associated with adverse clinicopathological factors and poor survival in a plethora of therapy‐naïve carcinoma entities including gastric adenocarcinoma (GC). As conventional histopathological grading is usually omitted in the post‐neoadjuvant setting of GC, our study aimed to investigate the prognostic impact of TB in GCs resected after neoadjuvant therapy. We evaluated TB according to the criteria from the International Tumour Budding Consensus Conference (ITBCC) in 167 post‐neoadjuvant resections of intestinal‐type GC and correlated the results with overall survival (OS) and clinicopathological parameters. GCs were categorised into Bd1 (0–4 buds, low TB), Bd2 (5–9 buds, intermediate TB), and Bd3 (≥10 buds, high TB). Carcinomas with intermediate and high TB were significantly enriched in higher ypTNM stages and strongly associated with reduced 5‐year OS in univariable analyses ( p < 0.001). In multivariable analyses including sex, age, resection status, UICC stage, and tumour regression grading, TB remained a stage‐independent predictor of survival ( p < 0.001, hazard ratio Bd2: 2.60, Bd3: 4.74). The assessment of TB according to the ITBCC criteria provides valuable prognostic information in the post‐neoadjuvant setting of intestinal‐type GC and may be a considerable substitute for the conventional grading system in GCs after neoadjuvant therapy.

show abstract

Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system

Abstract: ITBCC scoring is a simple, reliable and reproducible method to evaluate BD in PDAC and facilitates its documentation in histopathology reports, allowing the prognostic stratification of PDAC patients.

Cited by 35 publications

References 32 publications

Does evaluation of tumour budding in diagnostic biopsies have a clinical relevance? A systematic review

Does evaluation of tumour budding in diagnostic biopsies have a clinical relevance? A systematic review

Separation of Low- Versus High-grade Crohn’s Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis

Post‐neoadjuvant assessment of tumour budding according to ITBCC subgroups delivers stage‐ and regression‐grade independent prognostic information in intestinal‐type gastric adenocarcinoma

Contact Info

Product

Resources

About